OBJECTIVE: To prospectively investigate and detect early cerebral metabolic changes in patients with end-stage renal disease (ESRD) by using in vivo proton MR spectroscopy (MRS). METHODS: We enrolled 32 patients with ESRD and 32 healthy controls between the ages of 26 and 50 years. Short echo time single-voxel proton MRS was acquired from volumes of interest (VOIs) located in the frontal grey and white matter, temporal white matter and basal ganglia. The choline/phospatidylcholine (Cho), myo-inositol (mI), N-acetylaspartate (NAA) and total creatine (tCr) peaks were measured and the metabolic ratios with respect to tCr were calculated. RESULTS: In the ESRD group, significant elevations of the Cho/tCr and mI/tCr ratios were observed for the frontal grey matter, frontal white matter, temporal white matter and basal ganglia as compared with controls. There was no significant difference in the NAA/tCr ratios at all VOIs between the ESRD patients and the healthy controls. CONCLUSIONS: Proton MRS is a useful and non-invasive imaging tool for the detection of early cerebral metabolic changes in neurologically presymptomatic ESRD patients.
OBJECTIVE: To prospectively investigate and detect early cerebral metabolic changes in patients with end-stage renal disease (ESRD) by using in vivo proton MR spectroscopy (MRS). METHODS: We enrolled 32 patients with ESRD and 32 healthy controls between the ages of 26 and 50 years. Short echo time single-voxel proton MRS was acquired from volumes of interest (VOIs) located in the frontal grey and white matter, temporal white matter and basal ganglia. The choline/phospatidylcholine (Cho), myo-inositol (mI), N-acetylaspartate (NAA) and total creatine (tCr) peaks were measured and the metabolic ratios with respect to tCr were calculated. RESULTS: In the ESRD group, significant elevations of the Cho/tCr and mI/tCr ratios were observed for the frontal grey matter, frontal white matter, temporal white matter and basal ganglia as compared with controls. There was no significant difference in the NAA/tCr ratios at all VOIs between the ESRDpatients and the healthy controls. CONCLUSIONS: Proton MRS is a useful and non-invasive imaging tool for the detection of early cerebral metabolic changes in neurologically presymptomatic ESRDpatients.
Authors: W Hollingworth; L S Medina; R E Lenkinski; D K Shibata; B Bernal; D Zurakowski; B Comstock; J G Jarvik Journal: AJNR Am J Neuroradiol Date: 2006-08 Impact factor: 3.825
Authors: Alberto Martinez-Vea; Esther Salvadó; Alfredo Bardají; Cristina Gutierrez; Ana Ramos; Carmen García; Teresa Compte; Carmen Peralta; Montse Broch; Rosa Pastor; Pere Angelet; Luis Marcas; Amadeo Saurí; Jesús Angel Oliver Journal: Am J Kidney Dis Date: 2006-02 Impact factor: 8.860
Authors: Xiaoping Zhu; Norbert Schuff; John Kornak; Brian Soher; Kristine Yaffe; Joel H Kramer; Frank Ezekiel; Bruce L Miller; William J Jagust; Michael W Weiner Journal: Alzheimer Dis Assoc Disord Date: 2006 Apr-Jun Impact factor: 2.703